Obesity at Pediatric Cancer Diagnosis Linked to Inferior Survival
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 13, 2025 -- Obesity at cancer diagnosis is associated with inferior survival among children aged 2 to 18 years, according to a study published online Jan. 13 in Cancer.
Samuel Sassine, M.D., from the Centre Hospitalier Universitaire Sainte‐Justine in Montreal, and colleagues conducted a retrospective cohort study using the Cancer in Young People in Canada database, including children aged 2 to 18 years with newly diagnosed cancer from 2001 to 2020. Obesity was defined as age‐ and sex‐adjusted body mass index ≥95th percentile.
A total of 11,291 patients were included in the cohort; 10.5 percent had obesity at diagnosis. The researchers found that obesity at diagnosis was independently associated with inferior event-free survival (EFS) and overall survival (OS; adjusted hazard ratios, 1.16 and 1.29, respectively) in models controlling for age, sex, ethnicity, neighborhood income quintile, treatment era, and cancer categories. For acute lymphoblastic leukemia (ALL) and central nervous system (CNS) tumors, the adverse prognostic impact of obesity was particularly notable. In a multivariable analysis, obesity remained associated with inferior EFS and OS in 3,458 children with ALL (adjusted hazard ratios, 1.55 and 1.75, respectively). Obesity was also associated with inferior EFS and OS in 2,458 children with CNS tumors (adjusted hazard ratios, 1.38 and 1.47, respectively).
"Our study highlights the negative impact of obesity among all types of childhood cancers," co-senior author Thai Hoa Tran, M.D., also from the Centre Hospitalier Universitaire Sainte‐Justine, said in a statement. "It provides the rationale to evaluate different strategies to mitigate the adverse risk of obesity on cancer outcomes in future trials."
One author disclosed ties to Jazz Pharmaceuticals and Servier Pharmaceuticals.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 -- For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care...
Telehealth Intervention Beneficial for Seniors With Metastatic Cancer
WEDNESDAY, June 25, 2025 -- The telehealth-administered Geriatric Assessment–Guided Intervention (GAIN-S) improves physical function, mood, quality of life, and prognostic...
ADA: Weight Loss, Type 2 Diabetes Remission Up With Replacing Diet Drinks With Water
WEDNESDAY, June 25, 2025 -- For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.